Literature DB >> 19158238

Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals.

Stéphane Hué1, Robert J Gifford, David Dunn, Esther Fernhill, Deenan Pillay.   

Abstract

Transmission of human immunodeficiency virus (HIV) drug resistance is well-recognized and compromises response to first-line therapy. However, the population dynamics of transmitted resistance remains unclear, although previous models have assumed that such transmission reflects direct infection from treated individuals. We investigated whether population-based phylogenetic analyses would uncover lineages of resistant viruses circulating in untreated individuals. Through the phylogenetic analysis of 14,061 HIV type 1 (HIV-1) pol gene sequences generated in the United Kingdom from both treatment-naïve and -experienced individuals, we identified five treatment-independent viral clusters containing mutations conferring cross-resistance to antiretroviral drugs prescribed today in the United Kingdom. These viral lineages represent sustainable reservoirs of resistance among new HIV infections, independent of treatment. Dated phylogenies reconstructed through Bayesian Markov chain Monte Carlo inference indicated that these reservoirs originated between 1997 and 2003 and have persisted in the HIV-infected population for up to 8 years. Since our cohort does not represent all infected individuals within the United Kingdom, our results are likely to underestimate the number and size of the resistant reservoirs circulating among drug-naïve patients. The existence of sustained reservoirs of resistance in the absence of treatment has the capacity to threaten the long-term efficacy of antiretroviral therapy and suggests there is a limit to the decline of transmitted drug resistance. Given the current decrease in resistance transmitted from treated individuals, a greater proportion of resistance is likely to come from drug-naïve lineages. These findings provide new insights for the planning and management of treatment programs in resource-rich and developing countries.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158238      PMCID: PMC2648277          DOI: 10.1128/JVI.01556-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Transmission of drug-resistant HIV-1 in Europe remains limited to single classes.

Authors: 
Journal:  AIDS       Date:  2008-03-12       Impact factor: 4.177

2.  Update of the drug resistance mutations in HIV-1: Spring 2008.

Authors:  Victoria A Johnson; Françoise Brun-Vezinet; Bonaventura Clotet; Huldrych F Günthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman
Journal:  Top HIV Med       Date:  2008 Apr-May

3.  Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Authors:  Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

4.  Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.

Authors:  Andrew N Phillips; Clifford Leen; Alan Wilson; Jane Anderson; David Dunn; Achim Schwenk; Chloe Orkin; Teresa Hill; Martin Fisher; John Walsh; Deenan Pillay; Loveleen Bansi; Brian Gazzard; Philippa Easterbrook; Richard Gilson; Margaret Johnson; Caroline A Sabin
Journal:  Lancet       Date:  2007-12-08       Impact factor: 79.321

5.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.

Authors:  Brandon F Keele; Elena E Giorgi; Jesus F Salazar-Gonzalez; Julie M Decker; Kimmy T Pham; Maria G Salazar; Chuanxi Sun; Truman Grayson; Shuyi Wang; Hui Li; Xiping Wei; Chunlai Jiang; Jennifer L Kirchherr; Feng Gao; Jeffery A Anderson; Li-Hua Ping; Ronald Swanstrom; Georgia D Tomaras; William A Blattner; Paul A Goepfert; J Michael Kilby; Michael S Saag; Eric L Delwart; Michael P Busch; Myron S Cohen; David C Montefiori; Barton F Haynes; Brian Gaschen; Gayathri S Athreya; Ha Y Lee; Natasha Wood; Cathal Seoighe; Alan S Perelson; Tanmoy Bhattacharya; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-19       Impact factor: 11.205

6.  Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249.

Authors:  T Melby; R Demasi; N Cammack; G D Miralles; M L Greenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2007-11       Impact factor: 2.205

Review 7.  Raltegravir: an integrase inhibitor for HIV-1.

Authors:  Teresa H Evering; Martin Markowitz
Journal:  Expert Opin Investig Drugs       Date:  2008-03       Impact factor: 6.206

8.  BEAST: Bayesian evolutionary analysis by sampling trees.

Authors:  Alexei J Drummond; Andrew Rambaut
Journal:  BMC Evol Biol       Date:  2007-11-08       Impact factor: 3.260

9.  Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1.

Authors:  Robert J Gifford; Tulio de Oliveira; Andrew Rambaut; Oliver G Pybus; David Dunn; Anne-Mieke Vandamme; Paul Kellam; Deenan Pillay
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

10.  Episodic sexual transmission of HIV revealed by molecular phylodynamics.

Authors:  Fraser Lewis; Gareth J Hughes; Andrew Rambaut; Anton Pozniak; Andrew J Leigh Brown
Journal:  PLoS Med       Date:  2008-03-18       Impact factor: 11.069

View more
  55 in total

Review 1.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

2.  Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City.

Authors:  Delivette Castor; Andrea Low; Teresa Evering; Sharon Karmon; Brandi Davis; Amir Figueroa; Melissa LaMar; Donald Garmon; Saurabh Mehandru; Martin Markowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2012-09-01       Impact factor: 3.731

3.  Growth of HIV-1 Molecular Transmission Clusters in New York City.

Authors:  Joel O Wertheim; Ben Murrell; Sanjay R Mehta; Lisa A Forgione; Sergei L Kosakovsky Pond; Davey M Smith; Lucia V Torian
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

4.  Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.

Authors:  Arun K Ghosh; Bruno D Chapsal; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  Bioorg Med Chem Lett       Date:  2012-02-02       Impact factor: 2.823

5.  Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex.

Authors:  Arun K Ghosh; Margherita Brindisi; Prasanth R Nyalapatla; Jun Takayama; Jean-Rene Ella-Menye; Sofiya Yashchuk; Johnson Agniswamy; Yuan-Fang Wang; Manabu Aoki; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  Bioorg Med Chem       Date:  2017-04-09       Impact factor: 3.641

6.  Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.

Authors:  Arun K Ghosh; Jacqueline N Williams; Rachel Y Ho; Hannah M Simpson; Shin-Ichiro Hattori; Hironori Hayashi; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2018-10-24       Impact factor: 7.446

7.  Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.

Authors:  Arun K Ghosh; Zilei Xia; Satish Kovela; William L Robinson; Megan E Johnson; Daniel W Kneller; Yuan-Fang Wang; Manabu Aoki; Yuki Takamatsu; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2019-10-04       Impact factor: 3.466

8.  Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein.

Authors:  Luciano Vozzolo; Belinda Loh; Paul J Gane; Maryame Tribak; Lihong Zhou; Ian Anderson; Elisabeth Nyakatura; Richard G Jenner; David Selwood; Ariberto Fassati
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

9.  Highly active antiretroviral therapy is associated with decreased incidence of sexually transmitted diseases in a Taiwanese HIV-positive population.

Authors:  Shu-Hsing Cheng; Chin-Hui Yang; Yu-Mei Hsueh
Journal:  AIDS Patient Care STDS       Date:  2013-02-26       Impact factor: 5.078

10.  Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.

Authors:  Arun K Ghosh; W Sean Fyvie; Margherita Brindisi; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Manabu Aoki; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2017-11-24       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.